According to the Changchun Hi-Tech announcement, Jinsai Pharmaceutical, a holding subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the application for clinical trial registration of drugs produced domestically produced GenSci 133 injection has been approved and is intended to be used to treat osteoporosis. This drug is a self-developed PTH analog and RANKL antibody fusion protein. It is a class 1 therapeutic biological product and is expected to be injected subcutaneously every 3 to 6 months.

Zhitongcaijing · 2d ago
According to the Changchun Hi-Tech announcement, Jinsai Pharmaceutical, a holding subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the application for clinical trial registration of drugs produced domestically produced GenSci 133 injection has been approved and is intended to be used to treat osteoporosis. This drug is a self-developed PTH analog and RANKL antibody fusion protein. It is a class 1 therapeutic biological product and is expected to be injected subcutaneously every 3 to 6 months.